Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors
May 18 2023 - 8:00AM
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global
medical technology company focused on surgical solutions for the
treatment of spinal disorders, today announced the appointment of
Lori Mitchell-Keller to the Company's Board of Directors effective
May 16, 2023. Ms. Mitchell-Keller will serve as a member of the
Compensation and Audit Committees of the Board of Directors.
“We are pleased to welcome Lori to our Board,
marking another high-quality independent member addition,” said
Stavros G. Vizirgianakis, Chairman of Xtant’s Board of Directors.
“Her deep operations, information technologies, and marketing
expertise will be of significant value to Xtant. Lori’s appointment
underscores our commitment to our long-term growth strategy.”
“I am excited to join Xtant’s Board as the
Company enters its next phase of growth,” said Ms. Mitchell-Keller.
“Xtant’s leading orthobiologics and spine fixation business is
well-positioned to continue its upward trajectory as highlighted by
the recent acquisition of the Coflex product line, and I look
forward to providing my expertise in driving the Company’s
continued success.”
About Lori Mitchell-Keller
Ms. Mitchell-Keller has over thirty years of
experience in the software, consumer goods, wholesale distribution
and retail industries, including more than fifteen years focused on
market strategy and market development. From May 2020 to November
2022, she served as VP and Global General Manager of Industry
Solutions at Google Cloud, a company offering a suite of cloud
computing services. From June 2018 to May 2020, Ms. Mitchell-Keller
served as the President and Global General Manager, SAP Industries
at SAP Labs, LLC, a software company, where she previously served
in several other roles since 2007, including EVP and Global General
Manager, Consumer Industries; SVP and Global Head, Retail Industry
Business Unit; SVP, LoB Solution Management Idea-to-Delivery; SVP,
Suite Solution Management, Supply Chain, Product Lifecycle
Management and Manufacturing; and SVP, Business Suite Applications.
Prior to SAP, Ms. Mitchell-Keller held a variety of executive
positions at Manugistics, a software company, and Baxter/Allegiance
Healthcare.
Ms. Mitchell-Keller currently serves as a member
of the Board of Directors of Mitratech, a software company, and the
Madison House Autism Foundation. She previously served on the
Boards of Directors of the Food Marketing Institute and the
National Retail Federation. Ms. Mitchell-Keller holds a Master of
Business Administration in Management/Strategy and Marketing from
the J.L. Kellogg Graduate School of Management at Northwestern
University, a Master of Science in Operations Research from
Stanford University, and a Bachelor of Science in Industrial
Engineering from Iowa State University.
About Xtant Medical Holdings,
Inc.
Xtant Medical Holdings, Inc.
(www.xtantmedical.com) is a global medical technology company
focused on the design, development, and commercialization of a
comprehensive portfolio of orthobiologics and spinal implant
systems to facilitate spinal fusion in complex spine, deformity and
degenerative procedures. Xtant people are dedicated and talented,
operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and
registered trademarks of Xtant Medical Holdings, Inc. or its
affiliates, registered as indicated in the United States, and in
other countries. All other trademarks and trade names referred to
in this release are the property of their respective owners.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as “intends,”
‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’
‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going
forward,” similar expressions or the negative thereof, and the use
of future dates. Forward-looking statements in this release include
the belief that the Company is well positioned to continue its
upward trajectory and continued success. The Company cautions that
its forward-looking statements by their nature involve risks and
uncertainties, and actual results may differ materially depending
on a variety of important factors, including, among others: the
Company’s future operating results and financial performance; its
ability to increase or maintain revenue; risks associated with its
recent acquisition of the Coflex® product line; possible future
impairment charges to long-lived assets and goodwill and
write-downs of excess inventory if revenues continue to decrease;
the ability to remain competitive; the ability to innovate, develop
and introduce new products; the ability to engage and retain new
and existing independent distributors and agents and qualified
personnel and the Company’s dependence on key independent agents
for a significant portion of its revenue; the effect of COVID-19,
labor and hospital staffing shortages on the Company’s business,
operating results and financial condition, especially when they
affect key markets; the Company’s ability to implement successfully
its future growth initiatives and risks associated therewith; the
effect of inflation, increased interest rates and other
recessionary factors and supply chain disruptions; the effect of
product sales mix changes on the Company’s financial results;
government and third-party coverage and reimbursement for Company
products; the ability to obtain and maintain regulatory approvals
and comply with government regulations; the effect of product
liability claims and other litigation to which the Company may be
subject; the effect of product recalls and defects; the ability to
obtain and protect Company intellectual property and proprietary
rights and operate without infringing the rights of others; the
ability to service Company debt, comply with its debt covenants and
access additional indebtedness; the ability to obtain additional
financing on favorable terms or at all; and other factors.
Additional risk factors are contained in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2022 filed with
the Securities and Exchange Commission (SEC) on March 7, 2023 and
subsequent SEC filings by the Company, including its Quarterly
Report on Form 10-Q for the quarterly period ended March 31, 2023
filed with the SEC on May 4, 2023. Investors are encouraged to read
the Company’s filings with the SEC, available at www.sec.gov, for a
discussion of these and other risks and uncertainties. The Company
undertakes no obligation to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events, except as required by law. All forward-looking statements
attributable to the Company or persons acting on its behalf are
expressly qualified in their entirety by this cautionary
statement.
Investor Relations Contact
David CareyLazar FINN PartnersPh: 212-867-1762Email:
david.carey@finnpartners.com
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Apr 2024 to May 2024
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From May 2023 to May 2024